Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23495162 | 1.00 | LMNA (0.68) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL23495230 | 0.92 | LMNA (0.71) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL29436233 | 0.92 | LMNA (0.71) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL29436167 | 0.86 | LMNA (0.51) | LMNAMAPTTP53POLBKMT2A | |
| SCHEMBL23495115 | 0.86 | LMNA (0.51) | LMNAMAPTTP53POLBKMT2A | |
| SCHEMBL23495180 | 0.86 | LMNA (0.63) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL29436212 | 0.85 | LMNA (0.68) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL23495240 | 0.85 | LMNA (0.68) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL23495302 | 0.85 | LMNA (0.67) | LMNAMAPTTP53POLBALDH1A1 | |
| SCHEMBL29436189 | 0.85 | LMNA (0.67) | LMNAMAPTTP53POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340526-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12415794-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4248972-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20220081410-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2022-03-17 | — | — | US | disclosed |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | LMNA 340/4885MAPT 1863/4885TP53 4843/4885 |
| US-20220081410-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | LMNA 439/4885MAPT 1810/4885TP53 4800/4885 |
| US-12415794-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | LMNA 439/4885MAPT 1810/4885TP53 4800/4885 |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | LMNA 439/4885MAPT 1810/4885TP53 4800/4885 |
| US-20250340526-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | LMNA 439/4885MAPT 1810/4885TP53 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.